Megan Dover

Co-Founder & Principal, Cross-Border Impact Ventures

Role: Investigator

Sites: CDL-Toronto, CDL-Vancouver

Stream: Cancer

Megan Dover is the co-founder and principal of Cross Border Impact Ventures (CBIV). At CBIV, she invests in Series A stage health technology companies in North America and Europe that address unmet needs for women and children globally. Key health focus areas for the fund include maternal and newborn health, sexual and reproductive health and chronic conditions that impact women and children such as oncology, cardiovascular health, mental health, gut health and respiratory health.

She has in-depth experience in venture capital, impact investing, venture advisory, M&A, business strategy, financial planning and analysis and angel investing. Prior to the launch of CBIV, Megan was the senior investment manager for the Every Woman Every Child Innovation Marketplace at Grand Challenges Canada, and acted as a venture advisor to support the fundraising efforts of a portfolio of early-stage health technology companies in raising equity and grant capital. Megan brought expertise in a number of areas to the role, having previously held roles in finance and strategy for a public mining and metals company, worked in management consulting for a global consulting firm, has been part of an R&D team for a biotech startup and as an advisor and angel investor at the Creative Destruction Lab (CDL). Megan obtained her MBA from the Rotman School of Management at the University of Toronto, receiving a Dean’s list ranking. She also earned her engineering degree with honours from Queen’s University, specializing in biomedical research within chemical engineering.

Megan is passionate about supporting world-class technology companies that are scaling tech for good. She is also a big fan of women in STEM, women in business, women’s health, women leaders and more women supporting women.